These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 11933860)

  • 41. Nonalcoholic steatohepatitis--a histological perspective.
    Sakhuja P; Malhotra V
    Indian J Pathol Microbiol; 2006 Apr; 49(2):163-72. PubMed ID: 16933708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis].
    Jansen PL
    Ned Tijdschr Geneeskd; 2005 Feb; 149(6):289-94. PubMed ID: 15730035
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes.
    Kichian K; McLean R; Gramlich LM; Bailey RJ; Bain VG
    Can J Gastroenterol; 2003 Jan; 17(1):38-42. PubMed ID: 12560853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.
    Powell EE; Cooksley WG; Hanson R; Searle J; Halliday JW; Powell LW
    Hepatology; 1990 Jan; 11(1):74-80. PubMed ID: 2295475
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hematocrit is associated with fibrosis in patients with nonalcoholic steatohepatitis.
    Li Y; Liu L; Wang B; Wang J; Chen D
    Eur J Gastroenterol Hepatol; 2014 Mar; 26(3):332-8. PubMed ID: 24172912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonalcoholic fatty liver disease: from pathogenesis to patient care.
    Perlemuter G; Bigorgne A; Cassard-Doulcier AM; Naveau S
    Nat Clin Pract Endocrinol Metab; 2007 Jun; 3(6):458-69. PubMed ID: 17515890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonalcoholic fatty liver disease: is all the fat bad?
    Clouston AD; Powell EE
    Intern Med J; 2004 Apr; 34(4):187-91. PubMed ID: 15086699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonalcoholic fatty liver disease.
    Adams LA; Angulo P; Lindor KD
    CMAJ; 2005 Mar; 172(7):899-905. PubMed ID: 15795412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The usefulness of measuring liver stiffness by transient elastography for assessing hepatic fibrosis in patients with various chronic liver diseases.
    Tamano M; Kojima K; Akima T; Murohisa T; Hashimoto T; Uetake C; Sugaya T; Nakano M; Hiraishi H; Yoneda M
    Hepatogastroenterology; 2012 May; 59(115):826-30. PubMed ID: 22469726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural history of nonalcoholic steatohepatitis.
    Liou I; Kowdley KV
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S11-6. PubMed ID: 16540761
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.
    Ekstedt M; Franzén LE; Mathiesen UL; Kechagias S
    Scand J Gastroenterol; 2012 Jan; 47(1):108-15. PubMed ID: 22126450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD.
    Boursier J; Chaigneau J; Roullier V; Lainé F; Sandrini J; Michalak S; Hubert I; Dib N; Oberti F; Bertrais S; Hunault G; Deugnier Y; Rousselet MC; Cavaro-Ménard C; Gallois Y; Aubé C; Calès P;
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):974-81. PubMed ID: 21904208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pediatric nonalcoholic fatty liver disease.
    Bozic MA; Subbarao G; Molleston JP
    Nutr Clin Pract; 2013 Aug; 28(4):448-58. PubMed ID: 23917437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cryptogenic cirrhosis: a vanishing entity.
    Desai HG
    J Assoc Physicians India; 2009 Nov; 57():751-4, 759. PubMed ID: 20329442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.
    Younossi ZM; Stepanova M; Rafiq N; Makhlouf H; Younoszai Z; Agrawal R; Goodman Z
    Hepatology; 2011 Jun; 53(6):1874-82. PubMed ID: 21360720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [NASH -- nonalcoholic steatohepatitis].
    Blechacz B; Stremmel W
    Z Gastroenterol; 2003 Jan; 41(1):77-90. PubMed ID: 12541180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research.
    Kleiner DE; Brunt EM
    Semin Liver Dis; 2012 Feb; 32(1):3-13. PubMed ID: 22418883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies.
    Fassio E; Alvarez E; Domínguez N; Landeira G; Longo C
    Hepatology; 2004 Oct; 40(4):820-6. PubMed ID: 15382171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.